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Evaluation of the suitability of weekly peak
expiratory flow rate measurements in monitoring
annual decline in lung function among patients
with asthma and chronic bronchitis
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SUMMARY
Background. Early detection and treatment of patients with
asthma or chronic bronchitis who have a rapid annual
decline in lung function is essential in order to improve
their long-term prognosis. This annual rate of decline can
be assessed accurately by monitoring the forced expiratory
volume in one second (FEV,) which is a routine procedure
in hospital respiratory laboratories but not in general prac-
tice. General practitioners usually measure patients' peak
expiratory flow rate (peak flow) to evaluate lung function. If
annual decline in lung function can be assessed by mon-
itoring peak flow, this method could be used in general
practice for detecting patients at an early stage who have a
rapid decline.
Aim. A study aimed to investigate the long-term correlation
between FEV, and peak flow among a group of patients in
Nijmegen, the Netherlands.
Method. FEV, and peak flow were monitored in 53 patients
with moderate asthma and 78 patients with moderate
chronic bronchitis over four years. FEV, was measured in a
laboratory once every six months and peak flow was mea-
sured by patients once a week. The correlation between the
two sets of measurements was studied for each patient.
Results. Four-year data for 83 of the 131 patients were
analysed; the other 48 patients received inhaled steroids
during the second half of the study period so their data
were not considered for all the analyses. Of the 83
patients, 35 (42%) showed a decrease in both FEV, and
peak flow. Thirty six patients (43%) showed a decrease in
FEV, and an increase in peak flow. Four patients (5%)
showed an increase in FEV, and a decrease in peak flow
and eight patients (10%) showed an increase in both rates.
Approximately similar results were seen in a separate
analysis of all 131 patients during the first two years of the
study.
Conclusion. No long-term correlation was found between
FEV, and peak flow. Peak flow is not capable of detecting
annual decline in lung function. Therefore it cannot be used
to detect patients with asthma or chronic bronchitis who
have a rapid annual decline in lung function. Spirometers,
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which measure peak flow and FEVy, could be used in general
practice. These would allow general practitioners to con-
tinue measuring peak flow in order to assess short-term
changes in lung function while providing an important
means for monitoring FEV, to assess long-term changes in
lung function.
Keywords: asthma; airways obstruction; peak expiratory
flow recordings; lung function.
Introduction
1THERE is an increased appreciation of the importance of using
1 objective parameters such as peak expiratory flow rate (peak
flow) in the diagnosis and treatment of patients with asthma and
chronic bronchitis (chronic obstructive pulmonary disease)."2 The
peak flow represents the maximum flow of air attained during a
forced expiratory manoeuvre and corresponds to the peak on a
flow-volume curve. This maximum flow during expiration is
reduced in patients with airway obstruction, for example those
with asthma or chronic bronchitis. The rate has been shown to be
a simple and reproducible parameter in assessing airway obstruc-
tion.3 The peak flow meter is a cheap and simple device that is
commonly used in general practice and by asthmatic patients in
self-management programmes. A patient's measured peak flow
value can be compared with a predicted value (obtained from
standard reference charts) or with the patient's personal best
(measured during a symptom-free period) to determine the pres-
ence or absence of airway obstruction. Other common uses of
peak flow measurements are in the assessment of diumal variabil-
ity, day-to-day variability and reversibility of airway obstruction.4
The greater the variability the more prone are the airways to
bronchial constriction.
The forced expiratory volume in one second (FEVy) is another
objective parameter which has been established as the best meas-
ure for assessing severity of airway obstruction.3 Owing to the
complexity and high costs of the necessary apparatus it has until
recently only been used in hospital respiratory laboratories. Since
the introduction of portable, easy-to-use, low-cost spirometers,
patients' FEV, is occasionally being measured in general prac-
tice. FEV, has been shown to be an important index for assessing
severity of airway obstruction and for estimating its progression
and is so far the only parameter that has been shown to predict
asthma mortality.5 In adults, FEV, shows a physiological decline
with age.67 This annual rate of decline is greater in asthma and
chronic bronchitis sufferers compared with non-sufferers.8 It is
possible to detect patients with a high annual rate of decline in
lung function by means of serial FEV, measurements. Early
detection followed by adequate treatment of such patients has
been shown to reduce this rate of decline, thereby improving
patients' long-term prognosis.9
FEV, and peak flow measurements show a close correlation in
cross-sectional studies.'0 Although many longitudinal studies
have investigated the course of FEVy over time, little is known
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about the course of peak flow over time and its long-term corre-
lation with FEV,. If peak flow is shown to have a close long-term
correlation with FEV, it could be used in general practice to
detect patients with a fast, progressive form of asthma or chronic
bronchitis. A study was carried out to investigate the long-term
correlation between FEV, and peak flow.
Method
Patient selection and participation
The study was approved by the medical ethics committee of the
University of Nijmegen, the Netherlands. Twenty nine general
practitioners in the catchment area of the university selected
patients for the four-year study. A total of 223 patients aged 30
years or over with moderate airway obstruction owing to asthma
or chronic bronchitis were selected for the study."I Of the
patients selected, 131 (53 with asthma and 78 with chronic bron-
chitis) completed the four-year follow up during which FEV, and
peak flow measurements were made.
The only medication allowed during the first two years of the
study were the bronchodilators salbutamol or ipratropium brom-
ide. At the end of the second year the annual rate of decline in
FEVy was calculated for each patient by means of regression
analysis. Patients were then divided into two groups according to
the magnitude of their annual rate of decline. The first group
comprised 48 patients with an annual rate of decline in FEV,
greater than 0.08 1 year-' (26 of whom had asthma). The second
group comprised the 83 patients whose rate of decline in FEV,
was less than 0.08 1 year-' (27 of whom had asthma).
Beclomethasone dipropionate inhalations 400 jug twice daily
were added to the medication of all patients in the first group. No
additional medication was given to patients in the second group.
Both groups were monitored for a further two years.
FEV,
FEV, measurements were performed once every six months at
the Department of Pulmonology, Dekkerswald, the Netherlands
by two trained laboratory assistants. FEV, was measured using
an integrating flow meter (Microspiro HI-2980, Chest
Corporation).'2 Patients were instructed to refrain from bron-
chodilator therapy for at least eight hours before measurement.
At each measurement three forced expiratory manoeuvres were
carried out. The difference between the highest and the lowest
FEV, values had to be less than 0.1 1; if this was not the case,
patients were asked to try again after a few minutes' rest. The
FEV, of the attempt with the highest sum of FEV, and forced
vital capacity was retained for statistical analysis. All measure-
ments were made during periods free from exacerbations.
Exacerbations were defined according to Fletcher, modified
according to Boman and colleagues.'3 In total nine half-yearly
FEV, measurements per patient were available for analysis.
Peakflow
Peak flow was measured using an Assess® peak flow meter
(Health Scan Products).'4 All patients were given a peak flow
meter and were taught to measure their own rate. Patients were
asked to measure their peak flow once a week on the same day,
three times in the morning, and to record all results in a diary
card. All measurements were made before using bronchodilator
medication. The patient's technique in measuring and recording
peak flow was checked at each visit to the lung function labora-
tory. The highest of the three peak flow measurements was con-
sidered for analysis. In total, 208 weekly peak flow measure-
ments per patient were available for analysis.
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Patient symptoms and smoking history
Patients recorded their symptoms on the Dutch version of a
Medical Research Council respiratory symptoms questionnaire.
The numbers of symptoms recorded were added together and
presented as a score ranging from zero to eight. Smoking history
was assessed in pack years, a pack year being defined as 25 cigar-
ettes per day per year.
Longitudinal correlation between FEV, and peakflow
Data for all 131 patients were analysed for the first two years of
the study. Five FEV, and 104 peak flow measurements per
patient were considered for regression analysis. There were no
missing values during the first two years. The regression coeffi-
cient of the FEV, and of the peak flow were calculated and the
former was then plotted against the latter for each patient.
Data for the 83 patients in the group not receiving inhaled cor-
ticosteroids were analysed for the four years of the study. Nine
FEV, and 208 peak flow measurements per patient were consid-
ered for regression analysis. There was one missing FEV, value
in the third year and three in the fourth year, thus, four patients
had eight instead of nine FEV, measurements. In these cases the
regression coefficient was calculated for the available measure-
ments. For each of the 83 patients, the regression coefficient of
the FEV, was calculated and plotted against the regression coef-
ficient of the peak flow.
Cross-sectional correlation between FEV, and peakflow
FEV, was measured on nine occasions. Nine corresponding peak
flow values were obtained by calculating the mean of five con-
secutive weekly peak flow values for each FEV, value (the third
peak flow value corresponded with the week of FEVy measure-
ment). The mean FEV, and mean peak flow values for patients in
the first group (that is, patients who received inhaled cortico-
steroids during the third and fourth years of the study) and
patients in the second group (those who did not receive inhaled
corticosteroids) were then plotted on a time scale.
Patient characteristics associated with a high correlation
between FEV, and peakflow
A correlation coefficient of 0.6 or greater between the slopes of a
patient's FEV, and peak flow was defined as being a high cor-
relation and a correlation coefflcient of less than 0.6 was defined
as being low. Various patient characteristics, for example age,
symptom score, number of pack years of cigarettes, bronchial
hyper-responsiveness and percentage airway reversibility, were
analysed to determine whether any patient characteristics were
associated with a high correlation between FEV, and peak flow.
Statistical tests
The difference in the distribution of nominal variables between
patients who had a high or low correlation coefficient between
their FEV, and peak flow was tested using the chi square test.
Continuous variables were tested using the unpaired t-test. The
Wilcoxon test was used to test the difference in patients'
bronchial hyper-responsiveness.
Results
Longitudinal correlation between FEV, and peakflow
Two-year follow up. The relationship between the regression
coefficients of the FEVI and of the peak flow for each of the 131
patients during the first two years of the study is shown in Figure
1. In total 88 patients (67.2%), of whom 36 had asthma, showed
a decrease in FEV, and 59 patients (45.0%), of whom 19 had
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n= 41
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Figure 1. Relationship between the regression coefficients of FEVy
and peak expiratory flow rate (PEFR) for each of the 131 patients
during the first two years of the study, where . = patients with
asthma and A = patients with chronic bronchitis (n = number of
patients).
asthma, showed a decrease peak flow during this period. Forty
seven patients (35.9%), 16 of whom had asthma, showed a
decrease in both FEV, and peak flow. Forty one patients
(31.3%), 20 of whom had asthma, showed a decrease in FEV,
and an increase in peak flow. Twelve patients (9.2%), three of
whom had asthma, showed an increase in FEV, and a decrease in
peak flow. Thirty one patients (23.7%), 14 of whom had asthma,
showed an increase in both rates.
Four-year follow up. The relationship between the regression
coefficients of the FEV, and of the peak flow for each of the 83
patients not receiving inhaled corticosteroids followed up over
four years is shown in Figure 2. In total 71 patients (85.5%), 17
of whom had asthma, showed a decrease in FEV, and 39 patients
(47.0%), of whom 13 had asthma, showed a decrease in peak
flow during this period. Thirty five patients (42.2%), 10 of whom
had asthma, showed a decrease in both FEV, and peak flow.
Thirty six patients (43.4%), seven of whom had asthma, showed
a decrease in FEV, and an increase in peak flow. Four patients
(4.8%), three of whom had asthma, showed an increase in FEV,
Figure 2. Relationship between the regression coefficients of FEV1
and peak expiratory flow rate (PEFR) for each of the 83 patients
during the four-year period, where * = patients with asthma
and = patients with chronic bronchitis (n = number of patients).
n = 47
A
A
A X
0.4
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and a decrease in peak flow. Eight patients (9.6%), seven of
whom had asthma, showed an increase in both rates.
Cross-sectional correlation between FEV, andpeakflow
The mean FEV, and peak flow values for the 48 patients in the
first group and the 83 patients in the second group over the four
years are shown in Figure 3. Patients in the first group showed a
decline in FEV, of 0.16 1 year-' during the first two years of the
study while peak flow remained stable. Patients' FEV, and peak
flow increased during the initial six months of treatment with
inhaled corticosteroids (FEV, increased by 0.46 1 year1').
Although FEV, decreased after this initial treatment effect (by
0.10 1 year1') peak flow remained stable. The decline in FEV.
during this period was 0.06 1 year-' less than the rate of decline
before treatment with inhaled corticosteroids. FEV, of patients in
the second group showed a progressive decline over the four years
of the study while peak flow remained approximately the same.
Patient characteristics associated with a high correlation
between FEV, and peakflow
A total of 101 patients had a correlation coefficient of less than
0.6 between their FEVy and peak flow (low correlation group)
and 30 patients had a correlation coefficient of 0.6 or greater
(high correlation group). No patient characteristics were found to
be associated with a high correlation between FEVy and peak
flow (Table 1). Patient characteristics that were asthma-related
such as bronchial hyper-responsiveness, reversibility of airway
obstruction, atopy and a diagnosis of asthma, were associated
with a high correlation between FEV, and peak flow, but none of
the characteristics showed a significant difference between the
two groups.
Discussion
The present study failed to demonstrate a long-term correlation
between FEV, and peak flow in patients with moderate asthma or
chronic bronchitis. The majority of patients showed a long-term
decline in FEV, while only a few showed a decline in peak flow.
The percentage of patients showing a decline in FEV, increased
over time. There was, however, only a marginal increase in the
percentage of patients showing a decline in peak flow. The short-
term effect of inhaled corticosteroid treatment on the level of
FEV, and peak flow during the first half of the third year showed
a possible correlation on a group basis. Although asthma patients
showed a high correlation between peak flow and FEV, no
patient characteristics were found that could predict a high corre-
lation between the two rates. Hence it can be concluded that,
unlike the FEVI, peak flow is not capable of detecting the annual
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Figure 3. Mean FEV, and peak expiratory flow rate (PEFR) values
for 48 patients in the first group (those taking inhaled cortico-
steroids in the third and fourth years of the study) and 83 patients
in the second group (those not taking inhaled corticosteroids) over
the four years of the study.
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Table 1. Patient characteristics associated with a high or low cor-
relation between FEV, and peak expiratory flow rate (PEFR).
Characteristics of group in which
correlation between FEV, and PEFR
Patient characteristics Low (r< 0.6) High (r > 0.6)
No. of patients 101 30
Age (years) 52 50
Sex (no. of men) 59 13
Symptom score 5 5
No. of pack years
of cigarettes 17 16
Smoker (% of group) 56 40
FEV, (I sec-1) 2.4 2.2
FEV, (% of predicted value) 76 73
Bronchial hyper-
responsiveness (PC20)(mg ml-) 4 2
PEFR (I min-') 553 525
Reversibility of
airway obstruction (%) 16 22
Atopy (% of group) 24 33
Asthma (%of group) 36 57
decline in lung function in adults with moderate asthma or chron-
ic bronchitis.
The general practice management of asthma, including self-
management, is based on daily peak flow measurements, where-
by the 'traffic light' system of colour-coded peak flow measure-
ment zones provides the patient with an easy to understand
method of maintaining lung function at the highest possible
level.' The effect of appropriate medical intervention can also be
demonstrated by short-term monitoring of peak flow: the present
study showed a rise in peak flow during intervention with
inhaled corticosteroids. Peak flow has also been shown to be a
reliable measure of the reversibility of airways obstruction.4
Other investigations have shown a good short-term relationship
between peak flow and FEV,10 Peak flow can, therefore, be con-
sidered as a reliable parameter for monitoring short-term changes
in lung function in patients with asthma or chronic bronchitis.
FEV, provides an integrated index of the maximum flow dur-
ing +75% of the expiratory flow-volume curve.'5 Peak flow
mainly reflects the conductance in the central airways and is
responsible for only the initial part of the flow-volume curve.
Both FEVI and peak flow are known to be effort-dependent and
relatively insensitive to minor changes in the calibre of peri-
pheral airways. The time span within which the two parameters
are measured is therefore a possible explanation for the difference
in sensitivity to minor changes in maximum flow of air.
No long-term correlation was found to exist between peak
flow and FEV,. The consequence of this fact is of clinical impor-
tance. A patient with a stable peak flow, measured during con-
secutive consultations, can have a rapid decline in FEVy which
can proceed unnoticed if the FEVy is not assessed. Peak flow is
therefore not suitable for detecting patients at an early stage who
have a rapid decline in lung function. Since early detection and
treatment of patients with asthma or chronic bronchitis is the
only way to improve the long-term prognosis of these patients,
general practitioners could consider using a spirometer for mon-
itoring lung function in adults. Modem portable spirometers are
inexpensive and easy to use. In the near future much cheaper and
more accurate spirometers are expected. Almost all portable
spirometers also measure peak flow. Such an instrument would
allow general practitioners to continue measuring peak flow in
order to assess short-term changes in lung function while provid-
ing an important means for monitoring FEV, for the assessment
of long-term changes in lung function.
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